La Crosse Virus G1 Antibody (8C2.2): sc-57890

La Crosse Virus G1 Antibody (8C2.2) is a mouse monoclonal IgG2b antibody that detects La Crosse Virus G1 protein of La Crosse Virus origin by western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). Anti-La Crosse Virus G1 antibody (8C2.2) is available as the non-conjugated format. La Crosse Virus G1 protein plays a crucial role in the virus′s ability to infect host cells and evade the immune response, making La Crosse Virus G1 protein a key target for research into viral pathogenesis and potential therapeutic interventions. La Crosse Virus G1 protein is part of the virus′s envelope and is involved in the fusion of the viral membrane with the host cell membrane, a critical step for viral entry. Understanding the function of La Crosse Virus G1 protein is essential for developing vaccines and antiviral drugs, as research can provide insights into how the virus interacts with host cells and how La Crosse Virus G1 protein can be effectively targeted. La Crosse Virus is an arbovirus, specifically a Bunyavirus, that causes La Crosse encephalitis, a serious illness that can lead to severe neurological complications. La Crosse Virus cycles between the daytime-biting treehole mosquito, Aedes triseriatus, and vertebrate amplifier hosts in deciduous forest habitats, with the potential for transmission to humans. La Crosse Virus genome consists of three negative-sense RNA segments, with the large (L) segment encoding an RNA-dependent RNA polymerase, the medium (M) segment encoding a polyprotein precursor that is posttranslationally cleaved into the envelope glycoproteins G1 and G2, and a small (S) segment encoding the nucleocapsid protein. Symptoms of infection can range from mild, such as nausea and headache, to severe cases that may result in seizures, coma, paralysis, and permanent brain damage.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

La Crosse Virus G1 Antibody (8C2.2) References:

1. DNA-based vaccine against La Crosse virus: protective immune response mediated by neutralizing antibodies and CD4+ T cells.  |  Schuh, T., et al. 1999. Hum Gene Ther. 10: 1649-58. PMID: 10428210
2. DNA vaccination against La Crosse virus.  |  Pavlovic, J., et al. 2000. Intervirology. 43: 312-21. PMID: 11251387
3. Functional L polymerase of La Crosse virus allows in vivo reconstitution of recombinant nucleocapsids.  |  Blakqori, G., et al. 2003. J Gen Virol. 84: 1207-1214. PMID: 12692286
4. Quantitative trait loci conditioning transovarial transmission of La Crosse virus in the eastern treehole mosquito, Ochlerotatus triseriatus.  |  Graham, DH., et al. 2003. Insect Mol Biol. 12: 307-18. PMID: 12864911
5. La Crosse virus nonstructural protein NSs counteracts the effects of short interfering RNA.  |  Soldan, SS., et al. 2005. J Virol. 79: 234-44. PMID: 15596819
6. Quantitative analysis of La Crosse virus transcription and replication in cell cultures and mosquitoes.  |  Kempf, BJ., et al. 2006. Am J Trop Med Hyg. 74: 224-32. PMID: 16474075
7. A G1 glycoprotein epitope of La Crosse virus: a determinant of infection of Aedes triseriatus.  |  Sundin, DR., et al. 1987. Science. 235: 591-3. PMID: 3810159
8. Pseudotype formation with La Crosse virus glycoproteins.  |  Bupp, K. and González-Scarano, F. 1998. J Gen Virol. 79 (Pt 4): 667-71. PMID: 9568959
9. Short report: Diapause, transovarial transmission, and filial infection rates in geographic strains of La Crosse virus-infected Aedes triseriatus.  |  Woodring, J., et al. 1998. Am J Trop Med Hyg. 58: 587-8. PMID: 9598445

The preferred La Crosse Virus G1/G2 antibody is La Crosse Virus G1/G2 Antibody (10G5.4): sc-57891.